Tolrestat
ALIMENTARY TRACT AND METABOLISM
Also known as: alredase, AY-27773, lorestat, tolrestatin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Tolrestat is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1989. DrugCentral lists 9 molecular targets, including Akr1b1, AKR1B1 and AKR1B1. Recorded indications include Diabetic complication.
- Molecular targets: Akr1b1, AKR1B1, AKR1B1 and AKR1B1 (9 listed in DrugCentral).
- Indications: Diabetic complication.
- ATC code: A10XA01 (Aldose reductase inhibitors).
- Molecular formula: C16H14F3NO3S; molecular weight 357.35 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Diabetic complication
Mechanism & targets
Molecular targets (9)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Aldose reductase | Akr1b1 | unknown | IC50 8.70 |
| Aldose reductase | AKR1B1 | inhibitor | IC50 8.51 |
| Aldose reductase | AKR1B1 | unknown | IC50 7.82 |
| Aldose reductase | AKR1B1 | unknown | IC50 7.48 |
| Aldo-keto reductase family 1 member B10 | AKR1B10 | unknown | Ki 7.30 |
| Alcohol dehydrogenase [NADP(+)] | AKR1A1 | unknown | IC50 6.27 |
| Alcohol dehydrogenase [NADP(+)] | AKR1A1 | unknown | IC50 6.14 |
| Alcohol dehydrogenase [NADP(+)] | Akr1a1 | unknown | IC50 5.92 |
| Aldo-keto reductase family 1 member C21 | Akr1c21 | unknown | Ki 4.66 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1989-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A10XA01 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › OTHER DRUGS USED IN DIABETES › Aldose reductase inhibitors |
Chemical structure
| Molecular formula | C16H14F3NO3S |
|---|---|
| Molecular weight | 357.35 g/mol |
| CAS number | 82964-04-3 |
| InChIKey | LUBHDINQXIHVLS-UHFFFAOYSA-N |
| PubChem CID | 53359 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Tolrestat used for?
DrugCentral lists the following indications for Tolrestat: Diabetic complication.
How does Tolrestat work?
Its molecular targets in DrugCentral include Akr1b1, AKR1B1 (inhibitor), AKR1B1 and AKR1B1.
When was Tolrestat first approved?
Tolrestat was first approved by the YEAR INTRODUCED in 1989.
What is the chemical formula of Tolrestat?
Tolrestat has the molecular formula C16H14F3NO3S and a molecular weight of 357.35 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2704 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL436 — compound record and bioactivity
- PubChem CID 53359 — chemical identifiers
- DrugBank DB02383 — drug record
- FDA UNII 0T93LG5NMK — substance identity
- UniProt P15121 (AKR1B1) — target protein
- UniProt O60218 (AKR1B10) — target protein
- UniProt P14550 (AKR1A1) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.